BEAM Add to watchlist $30.68 +0.38 (+1.25%) Last updated: Apr 16, 2026 00:35
52-Week Range
$30.68
$15.35 $30.68 $36.44

Fundamentals Overview

Beam Therapeutics Inc. is in the middle of its 52-week range with premium valuation, trading relatively flat today.

Valuation premium

P/B 2.55 P/S 22.36

Risk (Beta)

2.19 — higher vol

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 60% confidence Risk: High Volatility — Beta 2.19. Consider smaller position size due to higher beta.

Supporting (Buy):

Sentiment improving (5 upgrades)

Pressures (Sell):

3M vs S&P 500: -9.6% · Beta 2.19 (elevated)

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$3.12B
P/E (TTM)
N/A
EPS (TTM)
N/A
Dividend Yield
N/A
52-Week Range
$15.35 - $36.44
Volume vs Avg
N/A
Beta
2.19

About

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for th...
Sector: Healthcare
Headquarters: US
Employees: 393
IPO Date: Feb 2020
Beta: 2.19 (More volatile than market)

Ratings & Grades at a Glance

Overall rating: C. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 15, Equal Weight: 2, Outperform: 3, Overweight: 4, Sector Outperform: 1, Sector Perform: 5.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $-37.99; current price is $30.68. That’s a -223.8% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) N/A
PEG (TTM) N/A
P/B (TTM) 2.55
P/S (TTM) 22.36
Liquidity & enterprise
Current Ratio (TTM) 13.09
Quick Ratio (TTM) 13.09
Cash Ratio (TTM) 3.04
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) -57.24%
Gross margin (TTM) -1.26%
Operating margin (TTM) -2.75%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for BEAM.

Analyst Sentiment at a Glance

C Sentiment Improving
Buy 15Equal Weight 2Outperform 3Overweight 4Sector Outperform 1Sector Perform 5
5 upgrades, 0 downgrades
Price Target Consensus
Current $30.68
Median $38.00
Consensus $40.83
Low consensus $26.00
High consensus $74.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Citigroup maintain Buy Buy 2026-03-26
RBC Capital maintain Sector Perform Sector Perform 2026-02-25
Wedbush maintain Outperform Outperform 2026-02-25
Bernstein maintain Outperform Outperform 2026-01-21
HC Wainwright & Co. maintain Buy Buy 2025-10-10
JP Morgan maintain Overweight Overweight 2025-10-09
HC Wainwright & Co. maintain Buy Buy 2025-09-15
Barclays maintain Equal Weight Equal Weight 2025-08-06
Guggenheim maintain Buy Buy 2025-05-07
Wells Fargo maintain Overweight Overweight 2025-05-07
Barclays maintain Equal Weight Equal Weight 2025-05-07
HC Wainwright & Co. maintain Buy Buy 2025-04-07
B of A Securities upgrade Neutral Buy 2025-03-28
Cantor Fitzgerald maintain Overweight Overweight 2025-03-12
Scotiabank upgrade Sector Perform Sector Outperform 2025-03-10
Jones Trading upgrade Hold Buy 2025-03-10
HC Wainwright & Co. maintain Buy Buy 2025-03-10
Scotiabank maintain Sector Perform Sector Perform 2025-03-03
HC Wainwright & Co. maintain Buy Buy 2025-02-28
Guggenheim maintain Buy Buy 2025-02-27
RBC Capital maintain Sector Perform Sector Perform 2025-02-26
HC Wainwright & Co. maintain Buy Buy 2025-02-03
Cantor Fitzgerald upgrade Neutral Overweight 2025-01-29
HC Wainwright & Co. maintain Buy Buy 2024-12-09
HC Wainwright & Co. maintain Buy Buy 2024-11-07
RBC Capital maintain Sector Perform Sector Perform 2024-11-06
Leerink Partners upgrade Market Perform Outperform 2024-11-06
RBC Capital maintain Sector Perform Sector Perform 2024-09-19
Stifel maintain Buy Buy 2024-09-11
HC Wainwright & Co. maintain Buy Buy 2024-08-22